Threshold
← Landscape

Trial NCT05874921

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

Phase
Not given
Sponsor
UroGen Pharma Ltd.
Conditions
Urothelial Carcinoma; Urothelial Carcinoma Recurrent; Urothelial Carcinoma Ureter; Urothelial Carcinoma Ureter Recurrent; Urothelial Cancer of Renal Pelvis; Urothelial Carcinoma of the Renal Pelvis and Ureter; Carcinoma, Transitional Cell; Transitional Cell Carcinoma of Renal Pelvis
Ages
18+ years
View on ClinicalTrials.gov ↗

Eligibility criteria

Highlighted: restrictions our model extracted, each a verbatim quote (pink = excludes outright, blue = only under conditions).

Inclusion Criteria: * Adults >18 years old and capable of giving informed consent. * Diagnosis of UTUC. * Receipt of at least 1 dose of JELMYTO after FDA approval (15 Apr 2020). Exclusion Criteria: * Incapable of giving informed consent (e.g., incarcerated individuals, individuals with dementia). * Receipt of 1 or more doses of JELMYTO (also referred to as UGN-101 or Mitogel in clinical development) before FDA approval (on or before 15 Apr 2020). * Pregnancy or lactation.Pregnancy * Unable to comply with protocol requirements (for prospective data capture). * Any medical or mental condition(s) that makes participation in the Registry inadvisable in the opinion of the Investigator (for prospective data capture).

Restrictions found (1)

Recruiting in Massachusetts

  • Mass General Brigham · Boston, Suffolk County
  • Brigham and Women's Hospital · Boston, Suffolk County